|Bid||166.86 x N/A|
|Ask||175.40 x N/A|
|Day's range||169.05 - 174.40|
|52-week range||115.30 - 345.20|
|Beta (5Y monthly)||1.73|
|PE ratio (TTM)||6.16|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Moderna (NASDAQ: MRNA) investors didn't need to have too much patience in the early days of the pandemic. The company brought its coronavirus vaccine candidate from drawing board to market in about nine months. Next year, though, Moderna investors may need to rely on their patience.
In the early days of the pandemic, investors bet Novavax (NASDAQ: NVAX) would be a coronavirus vaccine winner. When the biotech's vaccine candidate fell behind, though, investors lost faith. With its shares down almost 90% this year, you may be wondering if Novavax presents a great buying opportunity.